TREATMENT OF ACUTE NONLYMPHOCYTIC LEUKEMIA WITH ANTI-ANTIBODIES

项目III的总体目标是评估I-131的使用情况-- 标记抗髓系抗体和自体骨髓 移植治疗急性非淋巴细胞白血病。 这种方法是基于标记抗体能够 定位于骨髓间隙及外照射的应用 自体骨髓全身照射(TBI) 移植治疗急性淋巴细胞性白血病。我们将首先衡量 药物动力学、生物分布和相关辐射 不同剂量I-131标记抗髓系药物的剂量学研究 第二期(或以后)ANL患者的抗体水平 减刑。在我们实现了良好剂量测定的患者中， 我们将评估增加I-治疗剂量的效果 131标记抗体特别注意结合的能力 用于去除骨髓的抗体偶联物，回收 自体移植后的造血功能，以及 髓外毒性的性质和程度。如果有利的话 没有实现剂量测量，我们将评估替代方案 抗体、抗体形式(F(Ab)或F(ab‘)2)或抗体 输液时间表。

The overall goal of project III is to evaluate the use of I-131- labeled anti-myeloid antibodies and autologous marrow transplantation as treatment for acute nonlymphocytic leukemia. This approach is based on the ability of labeled antibody to localize to the marrow space and the utility of external beam total body irradiation (TBI) with autologous marrow transplantation in treating ANL. We will initially measure the pharmacokinetics, biodistribution and associated radiation dosimetry of varying doses of I-131-labeled anti-myeloid antibodies in patients with ANL in second (or subsequent) remission. In patients in whom we achieve favorable dosimetry, we will evaluate the effects of increasing therapeutic doses of I- 131-labeled antibody with particular attention to the ability of the antibody-conjugate to ablate marrow, recovery of hematopoiesis following autologous transplantation, and the nature and extent of extramedullary toxicities. If favorable dosimetry is not achieved we will evaluate alternatives antibodies, forms of antibody (F(ab) or F(ab')2), or antibody infusion schedules.